DR. MARLENE CANO MD
Prescription History 1861830721
Internal Medicine - Pulmonary Disease in Saint Louis, MO

NPI Status: Active since June 12, 2013

Contact Information

1 BARNES JEWISH HOSPITAL PLZ
DIV IM PULMONARY
SAINT LOUIS, MO
ZIP 63110
Phone: (314) 454-8762
Fax: (314) 454-7524

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MARLENE CANO MD, an active Pulmonary Disease specialist practicing in Saint Louis, MO. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 22 documented patient claims. Among these therapy options, the most frequently utilized medication is Atorvastatin Calcium, which accounts for 11 claims alone.

Medication Index

No matching medications currently found on file.

Atorvastatin Calcium

Generic Formulation: Atorvastatin CalciumSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
MO State Average Benchmarks
Peer Average Claims211.0
Peer Average 30-Day Fills488.7
Peer Average Days Supply14,424
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 94.8% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $34.35 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.12

State Avg Cost Per Claim

$11.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrrole and heptanoic acid derivative, HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITOR (statin), and ANTICHOLESTEREMIC AGENT that is used to reduce serum levels of LDL-CHOLESTEROL; APOLIPOPROTEIN B; and TRIGLYCERIDES. It is used to increase serum levels of HDL-CHOLESTEROL in the treatment of HYPERLIPIDEMIAS, and for the prevention of CARDIOVASCULAR DISEASES in patients with multiple risk factors.

Therapeutic Applications

Atorvastatin is used along with a proper diet to help lower bad cholesterol and fats (such as LDL, triglycerides) and raise good cholesterol (HDL) in the blood. It belongs to a group of drugs known as statins. It works by reducing the amount of cholesterol made by the liver. Lowering bad cholesterol and triglycerides and raising good cholesterol decreases the risk of heart disease and helps prevent strokes and heart attacks. In addition to eating a proper diet (such as a low-cholesterol/low-fat diet), other lifestyle changes that may help this medication work better include exercising, losing weight if overweight, and stopping smoking. Consult your doctor for more details.

Finasteride

Generic Formulation: FinasterideSpecialty: Critical Care (Intensivists)
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
MO State Average Benchmarks
Peer Average Claims65.0
Peer Average 30-Day Fills148.5
Peer Average Days Supply4,387
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.1% less volume than the regional standard for practitioners inside MO. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77.99 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.09

State Avg Cost Per Claim

$16.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.

Therapeutic Applications

Finasteride is used to shrink an enlarged prostate (benign prostatic hyperplasia or BPH) in adult men. It may be used alone or taken in combination with other medications to reduce symptoms of BPH and may also reduce the need for surgery. Finasteride may improve symptoms of BPH and provide benefits such as decreased urge to urinate, better urine flow with less straining, less of a feeling that the bladder is not completely emptied, and decreased nighttime urination. This medication works by decreasing the amount of a natural body hormone (DHT) that causes growth of the prostate. Finasteride is not approved for prevention of prostate cancer. It may slightly increase the risk of developing a very serious form of prostate cancer. Talk to your doctor about the benefits and risks. Women and children should not use this medication.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MARLENE CANO MD provides transparency into local medical care patterns within Saint Louis, MO.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.